A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 460 participants.
Also called NCT01455857
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 460 participants
- Sponsor
- Registry
-
NCT01455857
-
- Other papers using this trial's data
- Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01455857. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- ITCA 650
- Intervention (Other)
- ITCA placebo
- Lead sponsor
- Intarcia Therapeutics
Record details
- Record id
cardio:ct-nct01455857- Content hash
3e4c38d06d64b8a29f43fb6b3260c53af086fede16b83dd52d62cd1c9af1e280